August 4, 2014

Transaction Announcement

BOSTON, MA -- Dunn Rush & Co. LLC is pleased to announce recent closing of $29.6 million recapitalization of Lucid, Inc., d.b.a. Caliber Imaging & Diagnostics (“Caliber I.D.”).  Dunn Rush & Co. served as financial advisor to the Special Committee of the Board of Directors of Lucid, Inc. in connection with the recapitalization.

 

Caliber I.D. (www.caliberid.com) designs, develops and markets the proprietary, cutting-edge VivaScope® system – a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan™ procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. Caliber I.D. is based in Rochester, New York.  

 

Dunn Rush & Co. LLC was founded in 2009 to provide high quality merger and acquisition advisory services to middle market companies valued between $20 million and $250 million. Dunn Rush & Co. LLC has significant expertise in the following industry sectors: Business Services; Consumer; Defense & Security; Healthy Living; Instrumentation; Manufacturing & Distribution; Medical Technology & Services; and Technology, Software & Data Services. The Firm is a registered Broker-Dealer and is headquartered at 225 Franklin Street, Boston MA 02110. For further information, please visit our website at www.dunnrush.com or contact us at 617-451-0001.

What Clients are Saying About Dunn Rush

Want to find out more? Get in touch.